These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. Boglione L; Cariti G; Di Perri G; D'Avolio A J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932 [TBL] [Abstract][Full Text] [Related]
25. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527 [TBL] [Abstract][Full Text] [Related]
26. Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection. Aspord C; Bruder Costa J; Jacob MC; Dufeu-Duchesne T; Bertucci I; Pouget N; Brevot-Lutton O; Zoulim F; Bourliere M; Plumas J; Leroy V; PLoS One; 2016; 11(6):e0156200. PubMed ID: 27281019 [TBL] [Abstract][Full Text] [Related]
27. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385 [TBL] [Abstract][Full Text] [Related]
28. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467 [TBL] [Abstract][Full Text] [Related]
29. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study. Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363 [TBL] [Abstract][Full Text] [Related]
30. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. Ma H; Yang RF; Wei L J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146 [TBL] [Abstract][Full Text] [Related]
31. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? Vlachogiannakos J; Papatheodoridis GV Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089 [TBL] [Abstract][Full Text] [Related]
32. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216 [TBL] [Abstract][Full Text] [Related]
33. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831 [TBL] [Abstract][Full Text] [Related]
34. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987 [TBL] [Abstract][Full Text] [Related]
35. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL; Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834 [TBL] [Abstract][Full Text] [Related]
36. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858 [TBL] [Abstract][Full Text] [Related]
37. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy. Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147 [TBL] [Abstract][Full Text] [Related]
38. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients. Galmozzi E; Facchetti F; Grossi G; Loglio A; Viganò M; Lunghi G; Colombo M; Lampertico P Liver Int; 2018 Mar; 38(3):417-423. PubMed ID: 28732143 [TBL] [Abstract][Full Text] [Related]
39. Serum sPD-1 and sPD-L1 as predictive biomarkers for HBsAg clearance in HBeAg-negative CHB patients undergoing IFN-based therapy. Chen X; Zhang B; Song X; Qian T; Zheng X; Zhang Y; Xu W; Gao Z; Peng L; Xie C Aliment Pharmacol Ther; 2024 Sep; 60(5):593-603. PubMed ID: 38923559 [TBL] [Abstract][Full Text] [Related]
40. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B. Hagiwara S; Nishida N; Watanabe T; Ida H; Sakurai T; Ueshima K; Takita M; Komeda Y; Nishijima N; Osaki Y; Kudo M Antivir Ther; 2018; 23(6):513-521. PubMed ID: 29438098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]